OmniaBio Inc., a subsidiary of CCRM, launched July 1, 2022. OmniaBio is a contract development and manufacturing organization (CDMO) conducting process development and producing gene-modified cells and viral vectors for Phase I clinical trials to commercial-scale manufacturing. OmniaBio is bringing... Read more